Alaunos Therapeutics (TCRT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 3, 2025, with virtual participation available to shareholders.

• Shareholders are invited to vote on key proposals, including director elections, auditor ratification, compensation, and capital structure changes.

Voting matters and shareholder proposals

• Election of four directors to serve until the 2026 annual meeting or until successors are qualified.

• Ratification of Cherry Bekaert LLC as independent auditor for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation as disclosed in the proxy statement.

• Approval of a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the Board's discretion.

• Approval to increase authorized common stock from 5,000,000 to 50,000,000 shares.

• Amendment to the 2020 Equity Incentive Plan to increase issuable shares from 130,745 to 1,130,745.

• Proposal to adjourn the meeting if necessary to solicit additional votes.

Board of directors and corporate governance

• Four nominees for director positions are Dale Curtis Hogue, Jr., Robert W. Postma, Jaime Vieser, and Holger Weis.